Examples of 'idarucizumab' in a sentence
Meaning of "idarucizumab"
Idarucizumab is a noun that refers to a medication used as an antidote for the anticoagulant dabigatran
Show more definitions
- A monoclonal antibody designed for the reversal of anticoagulant effects of dabigatran.
How to use "idarucizumab" in a sentence
Basic
Advanced
idarucizumab
Idarucizumab is a specific reversal agent for dabigatran.
A causal relationship to idarucizumab could not be established.
Praxbind contains the active substance idarucizumab.
It is unknown whether idarucizumab is excreted in human milk.
Idarucizumab is available as an antidote to rapidly reverse the effects of dabigatran.
After treatment with idarucizumab proteinuria has been observed.
Renal impairment did not impact the reversal effect of idarucizumab.
This suggests that idarucizumab has no prothrombotic effect.
The active substance is idarucizumab.
Effect of idarucizumab on the exposure and anticoagulant activity of dabigatran.
An impact of hepatic impairment on the pharmacokinetics of idarucizumab is not expected.
Describe how idarucizumab reverses the anticoagulation effects of dabigatran.
Or paravenous administration of idarucizumab.
Preclinical investigations with idarucizumab have shown no interactions with.
Idarucizumab binds specifically to dabigatran and reverses its anticoagulant effect.
See also
Studies to assess the potential reproductive effects of idarucizumab have not been performed.
No dose adjustment for idarucizumab is required in patients with renal impairment.
Studies to evaluate the mutagenic and carcinogenic potential of idarucizumab have not been performed.
Idarucizumab exhibited multiphasic disposition kinetics and limited extravascular distribution.
A study sponsored by the manufacturer found that idarucizumab effectively reversed anticoagulation by dabigatran within minutes.
Thus idarucizumab will not reverse the effects of other anticoagulants.
Reversal was only evaluable for those patients showing prolonged coagulation times prior to idarucizumab treatment.
Idarucizumab is recommended for dabigatran reversal if there is an urgent procedure or bleeding.
Nine patients were re-dosed with idarucizumab.
The idarucizumab formulation did not produce haemolysis of human whole blood in vitro.
All nine patients were redosed within 6 days after the first idarucizumab dose.
Idarucizumab potently and specifically binds to dabigatran and its metabolites and neutralises their anticoagulant effect.
None of the patients re-dosed with idarucizumab tested positive for anti-idarucizumab antibodies.
Idarucizumab alone has shown no procoagulant effect measured as ETP.
The transient proteinuria usually peaked about 4 h after idarucizumab administration and normalised within.
Idarucizumab has been studied in 58 patients with varying degrees of hepatic impairment.
What Praxbind contains - The active substance is idarucizumab.
Additionally, no idarucizumab binding to human reproductive tissues was observed in a tissue cross-reactivity study.
Renal impairment did not impact the reversal effect of idarucizumab ( see section 5.2 ).
Hours after the idarucizumab infusion, re-administration of dabigatran etexilate resulted in expected anticoagulant activity.
In one subject, treatment-emergent anti - idarucizumab antibodies were detected after the second administration.
Idarucizumab effectively and rapidly reversed the life-threatening bleeding within 15 min after the injection.
All pigs survived at idarucizumab doses of approximately 2.5 and 5 g.
In a subgroup of 6 subjects, idarucizumab was administered a second time, two months after the first administration.
